Lotus Eye Hospital is a listed corporate hospital chain that promises to fix your vision but is itself trading at a P/E so high (411x) that even Lasik can’t correct it. Eight centers across Tamil Nadu and Kerala, 9,703 surgeries in FY23, and still a PAT of only ₹0.65 crore—this is the equivalent of charging ₹10,000 for an eye surgery and ending up with ₹2 profit after all the chai-samosa bills.
2. Introduction
Lotus Eye Hospital (LEHIL) has been around since 1990, which makes it old enough to have witnessed both Harshad Mehta’s scam and Baba Ramdev’s yoga IPO dreams. Despite being in the business of vision correction, the company itself seems shortsighted when it comes to profitability.
Let’s put it bluntly: The hospital has delivered 5-year sales growth of only 4% and profit growth of negative 13%, yet the stock price ran up 116% in 6 months. Investors are clearly not looking at the income statement—they’re just squinting at the price chart.
The business is stable, with revenue from medical services, lenses, and pharmacy. But margins are as thin as a lens wiped with a sweaty handkerchief. OPM was 6.5% in FY25, which is what Apollo spends on biscuits in its cafeteria.
The company has almost no debt (₹3.4 Cr), which is great—but maybe banks also refused because they saw the 1.2% ROE.
So, what’s the hype? Is this a hidden gem or just a penny stock that put on contact lenses and walked the ramp? Let’s examine.
3. Business Model – WTF Do They Even Do?
Lotus Eye is a corporate hospital chain focused on ophthalmology. They operate 8 centers across Tamil Nadu and Kerala—Coimbatore, Tiruppur, Salem, and Cochin being the big ones.
Services include everything you’ve seen in flashy eye clinic ads:
Lasik, SMILE, Touchfree Laser (aka fancy ways to fry your cornea).
Cataract surgeries (bread and butter of every eye hospital).
Paediatric Eye Care, Squint Surgery (fixing what kids inherit from watching too much Cartoon Network).
Refractive & Diabetic Eye Care (India’s diabetes epidemic is literally their business model).
Surgeries rose from 8,076 in FY22 to 9,703 in FY23—a healthy volume growth. But financial growth? That’s like asking your rickshaw driver if he takes UPI—“sir, only cash.”
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹13.5 Cr
₹12.9 Cr
₹11.5 Cr
+5%
+17%
EBITDA
₹1.5 Cr*
₹1.6 Cr*
-₹0.2 Cr*
-7%
—
PAT
₹0.54 Cr
₹0.62 Cr
₹0.25 Cr
-13%
+116%
EPS (₹)
0.26
0.30
0.12
-13%
+116%
*Derived from OPM%
Commentary: Revenues inching forward like Chennai traffic. PAT is barely positive—if this were a cricket score, it’s like defending 90 runs in 20 overs.
5. Valuation – Fair Value Range Only
P/E Method: EPS ₹0.31. Industry average P/E ~62. Fair range = 30×–60× = ₹9 – ₹18. Current price ₹129 is basically standing on stilts.
EV/EBITDA Method: EV = ₹266 Cr, EBITDA ~₹4.4 Cr TTM. EV/EBITDA ~60. Fair industry multiple ~15–20. Fair range = ₹30 – ₹45.
